Why the study?
Does the source of live oral poliovaccine affect virus excretion and mutation rates in infants following primary vaccination?
Does the source of live oral poliovaccine affect virus excretion and mutation rates in infants following primary vaccination?
Answers are grounded in this paper and cite their sources.
The study demonstrates that different poliovirus serotypes have varying rates of excretion and mutation reversion in the gut, which may explain the distribution of vaccine-associated cases.
The excretion of virus by 30 children was followed over a period of 28 days after their first vaccination with live oral poliovaccine. The type 1 and type 2 strains were isolated at similar high frequencies throughout this period, while the type 3 strain was not excreted by most children after day 2 post vaccination. Mutations in the 5' non-coding region associated with the attenuated phenotype reverted most rapidly for type 3 and least rapidly for type 1. The data are consistent with different degrees of selection against the attenuating mutations in the three serotypes in the gut, but imply that reversion is required for prolonged excretion. The findings also provide a possible explanation for the reported distribution of the rarely occurring vaccine associated cases between recipients and contacts for the three serotypes. A statistically significant difference was not observed between vaccine from the two main suppliers to the UK market.
No takes yet. Share an insight, caveat, or question.
Dunn et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: